StockData
Ionis Pharmaceuticals Inc logo

Ionis Pharmaceuticals Inc (IONS) stock

IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/303% below fair value
$27.39+0.43 (+1.59%)

Close on Nov 18, 2026Market cap $4.55BP/E –Yield –

Ionis Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Ionis Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $874.09M, down 7.4% year over year. For fiscal 2025 it was $943.71M, up 33.8% from the year before. Over ten years it grew 12.8% a year on average. The highest annual figure on record is $1.12B in fiscal 2019.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$943.71M+33.8%
FY2024Dec 31, 2024$705.14M-10.5%
FY2023Dec 31, 2023$787.65M+34.1%
FY2022Dec 31, 2022$587.37M-27.5%
FY2021Dec 31, 2021$810.46M+11.1%
FY2020Dec 31, 2020$729.26M-35.0%
FY2019Dec 31, 2019$1.12B+87.2%
FY2018Dec 31, 2018$599.67M+16.6%
FY2017Dec 31, 2017$514.18M+37.9%
FY2016Dec 31, 2016$372.78M+31.4%
FY2015Dec 31, 2015$283.70M+32.5%
FY2014Dec 31, 2014$214.16M+45.4%
FY2013Dec 31, 2013$147.29M+44.3%
FY2012Dec 31, 2012$102.05M+3.0%
FY2011Dec 31, 2011$99.09M-8.7%
FY2010Dec 31, 2010$108.47M-10.8%
FY2009Dec 31, 2009$121.60M+13.4%
FY2008Dec 31, 2008$107.19M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$267.95M-40.7%
Q1 FY2026Mar 31, 2026$246.09M+87.0%
Q4 FY2025Dec 31, 2025$203.33M-10.3%
Q3 FY2025Sep 30, 2025$156.72M+17.1%
Q2 FY2025Jun 30, 2025$452.05M+100.7%
Q1 FY2025Mar 31, 2025$131.61M+10.1%
Q4 FY2024Dec 31, 2024$226.58M-30.2%
Q3 FY2024Sep 30, 2024$133.81M-7.2%
Q2 FY2024Jun 30, 2024$225.25M+19.6%
Q1 FY2024Mar 31, 2024$119.50M-8.4%
Q4 FY2023Dec 31, 2023$324.51M+113.6%
Q3 FY2023Sep 30, 2023$144.21M-9.7%
Q2 FY2023Jun 30, 2023$188.41M+40.8%
Q1 FY2023Mar 31, 2023$130.52M-8.0%
Q4 FY2022Dec 31, 2022$151.89M-65.5%
Q3 FY2022Sep 30, 2022$159.77M+20.0%
Q2 FY2022Jun 30, 2022$133.79M+6.4%
Q1 FY2022Mar 31, 2022$141.92M+27.2%
Q4 FY2021Dec 31, 2021$440.01M+51.6%
Q3 FY2021Sep 30, 2021$133.09M-16.9%
Q2 FY2021Jun 30, 2021$125.75M-13.6%
Q1 FY2021Mar 31, 2021$111.61M-16.3%
Q4 FY2020Dec 31, 2020$290.28M-41.2%
Q3 FY2020Sep 30, 2020$160.08M-4.7%
Q2 FY2020Jun 30, 2020$145.54M-11.2%
Q1 FY2020Mar 31, 2020$133.37M-55.1%
Q4 FY2019Dec 31, 2019$493.68M+157.0%
Q3 FY2019Sep 30, 2019$167.89M+15.5%
Q2 FY2019Jun 30, 2019$163.81M+39.1%
Q1 FY2019Mar 31, 2019$297.21M+105.8%
Q4 FY2018Dec 31, 2018$192.11M+14.5%
Q3 FY2018Sep 30, 2018$145.40M+22.9%
Q2 FY2018Jun 30, 2018$117.75M+4.9%
Q1 FY2018Mar 31, 2018$144.42M+24.7%
Q4 FY2017Dec 31, 2017$167.79M+4.6%
Q3 FY2017Sep 30, 2017$118.31M+6.7%
Q2 FY2017Jun 30, 2017$112.27M–
Q1 FY2017Mar 31, 2017$115.80M–
Q4 FY2016Dec 31, 2016$160.35M–
Q3 FY2016Sep 30, 2016$110.93M–

More Ionis Pharmaceuticals figures

See a number that looks wrong?